Skip to main content

Advertisement

SpringerLink
Log in

Category III Symptom-Modifying Antirheumatic Drugs

A Comparative Review

  • Review Article
  • Drug Class Overview
  • Published:
Clinical Immunotherapeutics Aims and scope Submit manuscript

Summary

The antirheumatic drugs used in the treatment of rheumatoid arthritis have recently been reclassified. There are 2 main groups: (a) symptom-modifying antirheumatic drugs, including nonsteroidal anti-inflammatory drugs (category I), corticosteroids (category II) and slower-acting drugs such as gold, methotrexate, sulfasalazine and cytotoxic agents (category III); and (b) disease-controlling anti-rheumatic therapy.

The category III symptom-modifying drugs are compared, in particular methotrexate with sulfasalazine; gold with penicillamine; cyclophosphamide with azathioprine; cyclosporin; and hydroxychloroquine with chloroquine. Comparative studies of these drugs include a meta-analysis of short term trials (<1 year), with the end-points being drug efficacy and toxicity. The drugs with the best efficacy: toxicity ratio were hydroxychloroquine and methotrexate. From these studies, methotrexate is the drug of first choice for mild to severe rheumatoid arthritis. Hydroxychloroquine with its low toxicity is the drug of choice for mild rheumatoid arthritis.

These data are also supported by survival analysis of drug therapy. If duration of therapy is assumed to be a measure of efficacy in the long term, then methotrexate is the most effective drug and hydroxychloroquine the least toxic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jeurissen MEC, Boerbooms AMTH, van der Putte LBA, et al. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis: a double blind study. Ann Intern Med 1991; 114: 999–1004

    PubMed  CAS  Google Scholar 

  2. Van der Heijde DM, Van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 335: 1036–8

    Article  Google Scholar 

  3. Co-operating Clinics Committee of the American Rheumatology Association. A controlled trial of cyclophosphamide in rheumatoid arthritis. N Engl J Med 1970; 283: 883–9

    Article  Google Scholar 

  4. Ianuzzi L, Dawson N, Zein N. Does drug therapy slow radiological deterioration in rheumatoid arthritis? N Engl J Med 1983; 309: 1023–7

    Article  Google Scholar 

  5. Wilske K, Healey L. Remodelling the pyramid: a concept whose time has come. J Rheumatol 1989; 16: 565–7

    PubMed  CAS  Google Scholar 

  6. Bensen WG, Bensen W, Adachi JD. Remodelling the pyramid: the therapeutic target of rheumatoid arthritis. J Rheumatol 1990; 17: 987–9

    PubMed  CAS  Google Scholar 

  7. van de Putte LBA, van Riel PLCM. Do disease-modifying antirheumatic drugs actually modify disease course in rheumatoid arthritis? Clin Immunother 1994; 1(5): 319–22

    Article  Google Scholar 

  8. Edmonds JP, Scott DL, Furst DE, et al. Antirheumatic drugs: a proposed new classification [editorial]. Arthritis Rheum 1993; 36; 336–9

    Article  PubMed  CAS  Google Scholar 

  9. Edmonds J. Reclassification of antirheumatic drugs: how and why? Clin Immunother 1994; 1(2) 110–6

    Article  Google Scholar 

  10. Segal R, Yaron M, Tartokovsly B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990; 20: 190–9

    Article  PubMed  CAS  Google Scholar 

  11. Selhub J, Dhar GJ, Rosenberg IH. Inhibition of folate enzymes by sulphasalazine. J Clin Invest 1978; 61: 221–4

    Article  PubMed  CAS  Google Scholar 

  12. Kremer J, Galivan J, Kamen B, et al. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Arthritis Rheum 1986; 29: 832–5

    Article  PubMed  CAS  Google Scholar 

  13. Miller LC, Cohen EE, Oreniole SF, et al. Interleukin-1 is structurally related to dihydrofolate reductase: effects of methotrexate on IL-1 [abstract]. Cytokine Res 1988; 7: 49

    Google Scholar 

  14. Hoult JR. Pharmacological and biochemical actions of sulphasalazine. Drugs 1986: 32 Suppl. 1: 18–26

    Article  PubMed  CAS  Google Scholar 

  15. American Society of Hospital Pharmacists. American hospital formulary service drug information 1994. Bethesda: American Society of Hospital Pharmacists, 1994

    Google Scholar 

  16. Kevat S, Ahern M, Hall P, et al. Hepatotoxicity of methotrexate in rheumatic disease. Med Toxicol 1988; 3: 197–208

    Article  CAS  Google Scholar 

  17. Ahern MJ, Kevat S, Hill W, et al. Hepatic methotrexate context and progression of hepatic fibrosis — preliminary findings. Ann Rheum Dis 1991; 50: 477–80

    Article  PubMed  CAS  Google Scholar 

  18. Herman RA, Van Pedersen P, Hoffman J, et al. Pharmacokinetics of low dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989; 78: 165–71

    Article  PubMed  CAS  Google Scholar 

  19. Neumann VC, Grindulis KA, Hubball S, et al. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds, Birmingham trial. BMJ Clin Res 1983; 287: 1099–102

    Article  CAS  Google Scholar 

  20. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818–22

    Article  PubMed  CAS  Google Scholar 

  21. Mielants H, Veys E, Joos R. Sulphasalazine in the treatment of enterogenic reactive arthritis and ankylosing spondylitis with peripheral arthritis. Clin Rheumatol 1986; 5: 80–3

    Article  PubMed  CAS  Google Scholar 

  22. Farr M, Kitas G, Waterhouse L, et al. Sulphasalazine in psoriatic arthritis: a double-blind placebo controlled study. Br J Rheumatol 1990; 29: 46–9

    Article  PubMed  CAS  Google Scholar 

  23. Weinblatt ME, Weismann BN, Coblyn JS, et al. Long term prospective study of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 129–37

    Article  PubMed  CAS  Google Scholar 

  24. Hanrahan PS, Scrivens GA, Russell AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol 1989; 28: 147–53

    Article  PubMed  CAS  Google Scholar 

  25. Nordstrom DM, West SG, Andersen PA, et al. Pulse methotrexate therapy in rheumatoid arthritis: a controlled prospective roentgenographic study. Ann Intern Med 1987; 107: 797–801

    PubMed  CAS  Google Scholar 

  26. Reykdal S, Steinsson K, Sigurjonsson K, et al. Methotrexate treatment of rheumatoid arthritis: effects on radiological progression. Scand J Rheumatol 1989; 18: 221–6

    Article  PubMed  CAS  Google Scholar 

  27. Sany J, Kaliski S, Couret M, et al. Radiologic progression during intramuscular methotrexate treatment of rheumatoid arthritis. J Rheumatol 1990; 17: 1636–41

    PubMed  CAS  Google Scholar 

  28. Kremer JM, Phelps CT. Long term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 138–45

    Article  PubMed  CAS  Google Scholar 

  29. Walker AM, Funch D, Dreyer N, et al. Determinants of serious liver disease among patients receiving low dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993; 36: 329–35

    Article  PubMed  CAS  Google Scholar 

  30. Skosey JL. Comparison of responses to and adverse effects of graded doses of sulfasalazine in the treatment of rheumatoid arthritis. J Rheumatol 1988; Suppl. 16: 5–8

    Google Scholar 

  31. Shiroky JB, Neville C, Esdaile JM, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Arthritis Rheum 1993; 36: 795–803

    Article  PubMed  CAS  Google Scholar 

  32. Kremer JM, Alarcon GS, Furst DE, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994: 37; 316–28

    Article  PubMed  CAS  Google Scholar 

  33. Furst DE, Kremer JM. Methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 305–14

    Article  PubMed  CAS  Google Scholar 

  34. Sherlock S. The spectrum of hepatotoxicity due to drugs. Lancet 1986; ii: 440–4

    Article  Google Scholar 

  35. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long term methotrexate therapy. Arthritis Rheum 1989; 32: 121–7

    Article  PubMed  CAS  Google Scholar 

  36. Whiting-O’Keefe QE, Eye KH, Sack KD, et al. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711–6

    PubMed  Google Scholar 

  37. Kremer J. Liver biopsies in patients with rheumatoid arthritis receiving methotrexate: where are we going [editorial]? J Rheumatol 1992; 2: 189–91

    Google Scholar 

  38. Farr M, Tunn EJ, Symmons DPM, et al. Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy. Br J Rheumatol 1989; 28: 134–8

    Article  PubMed  CAS  Google Scholar 

  39. Hopkinson ND, Garcia FS, Gumpel JM. Haematological side effects of sulphasalazine in inflammatory arthritis. Br J Rheumatol 1989; 28: 414–7

    Article  PubMed  CAS  Google Scholar 

  40. Al-Awadhi A, Dale P, McKendry RJ. Pancytopenia associated with low dose methotrexate therapy: a regional study. J Rheumatol 1993; 20: 1121–5

    PubMed  CAS  Google Scholar 

  41. Shiroky JB, Frost A, Skelton JD, et al. Complications of immunosuppression associated with weekly low dose of methotrexate. J Rheumatol 1991; 18: 1172–5

    PubMed  CAS  Google Scholar 

  42. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis. J Rheumatol 1987; 14: 1164–7

    PubMed  CAS  Google Scholar 

  43. Wang KK, Bowyer BA, Fleming CR, et al. Pulmonary infiltrates and eosinophilia associated with sulfasalazine. Mayo Clin Proc 1984; 59: 343–6

    Article  PubMed  CAS  Google Scholar 

  44. Jordan A, Cowan RE. Reversible pulmonary disease and eosinophilia associated with sulphasalazine. J R Soc Med 1988; 81: 233–5

    PubMed  CAS  Google Scholar 

  45. Gold R. Development of multiple sclerosis in patients on long term sulfasalazine. Lancet 1990; 335: 409–10

    Article  PubMed  CAS  Google Scholar 

  46. Birnie G. Incidence of sulphasalazine induced infertility. Gut 1981; 22: 452–5

    Article  PubMed  CAS  Google Scholar 

  47. Newman NM, Correy JF. Possible teratogenicity of sulfasalazine. Med J Aust 1983; 1: 528–9

    PubMed  CAS  Google Scholar 

  48. Ahern MJ, Booth J, Meffin P, et al. Methotrexate kinetics in rheumatoid arthritis: is there an interaction with non-steroidal anti-inflammatory drugs? J Rheumatol 1988; 15: 1356–60

    PubMed  CAS  Google Scholar 

  49. Felson D, Anderson J, Meenan R. The comparative efficacy and toxicity of second line drugs in rheumatoid arthritis: results of two meta analyses. Arthritis Rheum 1990; 33: 1449–61

    Article  PubMed  CAS  Google Scholar 

  50. Corkhill MM, Kirkham BW, Haskard DO, et al. Treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1. J Rheumatol 1991; 18: 1453–60

    Google Scholar 

  51. Ledson MJ, Bucknall RC, Edward SW. Inhibition of neutrophil oxidant secretion by D-penicillamine. Ann Rheum Dis 1992; 51: 321–5

    Article  PubMed  CAS  Google Scholar 

  52. Sigler JW, Bluhm GB, Duncan H, et al. Gold salts in the treatment of rheumatoid arthritis. Ann Intern Med 1974; 80: 21–6

    PubMed  CAS  Google Scholar 

  53. Blocka K, Furst D, Landaw E, et al. Single dose pharmacokinetics of auranofin in rheumatoid arthritis. J Rheumatol 1982; 9 Suppl. 8: 110–9

    Google Scholar 

  54. Dahl SL. Lack of correlation between blood gold concentrations and clinical response in patients with definite of classic RA receiving auranofin or gold sodium thiomalate. Arthritis Rheum 1985; 28: 1211

    Article  PubMed  CAS  Google Scholar 

  55. Heath MJ. Measurement of ‘free’ gold in patients receiving disodium aurothiomalate and the association of high free to total gold levels with toxicity. Ann Rheum Dis 1988; 47: 18

    Article  PubMed  CAS  Google Scholar 

  56. Furst DE, Levine S, Srinivasan S, et al. A double blind trial of high versus conventional dosages of gold salts for rheumatoid arthritis. Arthritis Rheum 1977; 20: 1473–80

    Article  PubMed  CAS  Google Scholar 

  57. Cats A. A multicenter controlled trial of the effects of different dosage of gold therapy, followed by maintenance therapy. Agents Actions 1976; 6: 355

    Article  PubMed  CAS  Google Scholar 

  58. Seideman P, Lindstrom B. Pharmacokinetic interactions of penicillamine in rheumatoid arthritis. J Rheumatol 1989; 16: 473–4

    PubMed  CAS  Google Scholar 

  59. Multicenter Trial Group. Controlled trial of D-penicillamine in severe rheumatoid arthritis. Lancet 1973; ii: 275–80

    Article  Google Scholar 

  60. Day AT. Penicillamine in rheumatoid disease, a long term study. BMJ 1974; 1: 180–3

    Article  PubMed  CAS  Google Scholar 

  61. Shiokawa Y. Clinical evaluation of D-penicillamine by multicentre double blind comparative study in chronic rheumatoid arthritis. Arthritis Rheum 1977; 20: 1464–72

    Article  PubMed  CAS  Google Scholar 

  62. Williams HJ. Low dose D-penicillamine therapy in rheumatoid arthritis: a controlled double blind clinical trial. Arthritis Rheum 1983; 26: 581–92

    Article  PubMed  CAS  Google Scholar 

  63. Furst DE. Rational use of disease modifying antirheumatic drugs. Drugs 1990; 39: 19–37

    Article  PubMed  CAS  Google Scholar 

  64. Tozman ECS, Gottlieb NL. Adverse reactions with oral and parenteral gold preparations. Med Toxicol 1987; 2: 177–89

    Article  PubMed  CAS  Google Scholar 

  65. Hall CL. The natural course of gold nephropathy: long term study of 21 patients. BMJ 1987; 295: 745–8

    Article  PubMed  CAS  Google Scholar 

  66. Coblyn JS. Gold induced thrombocytopenia: a clinical and immunogenetic study of twenty-three patients. Ann Intern Med 1981; 95: 178–81

    PubMed  CAS  Google Scholar 

  67. Foster RT. Eosinophilia: a marker of gold toxicity. Can J Hosp Pharm 1985; 85: 150–1

    Google Scholar 

  68. Heuer M, Pietrusko R, Morris R, et al. An analysis of worldwide safety experience with auranofin. J Rheumatol 1985; 12: 695–9

    PubMed  CAS  Google Scholar 

  69. Levy RS. Penicillamine: review and cutaneous manifestations. J Am Acad Dermatol 1983; 8: 548–58

    Article  PubMed  CAS  Google Scholar 

  70. Thomas D. Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine. Ann Rheum Dis 1984; 43: 402–6

    Article  PubMed  CAS  Google Scholar 

  71. Speth PAJ. Thrombotic thrombocytopenic purpura associated with D-penicillamine treatment in rheumatoid arthritis. J Rheumatol 1982; 9: 812–3

    PubMed  CAS  Google Scholar 

  72. Anonymous. Penicillamine nephropathy [editorial]. BMJ Clin Res 1981; 282: 761–2

  73. Bacon PA, Tribe CR, Mackenzie JC, et al. Penicillamine nephropathy in rheumatoid arthritis: a clinical pathological and immunological study. Q J Med 1976; 45: 661

    PubMed  CAS  Google Scholar 

  74. Stockman A. Genetic markers in rheumatoid arthritis: relationship to toxicity from D-penicillamine. J Rheumatol 1986; 13: 269–73

    PubMed  CAS  Google Scholar 

  75. Moens HJB. Long term follow up of treatment with D-penicillamine for rheumatoid arthritis: efficacy and toxicity in relation to HLA antigens. J Rheumatol 1987; 14: 1115–9

    PubMed  CAS  Google Scholar 

  76. Gibson T. Goodpastures syndrome and D-penicillamine. Ann Intern Med 1976; 84: 100

    PubMed  CAS  Google Scholar 

  77. Webley M, Coomes EN. Is penicillamine therapy in rheumatoid arthritis influenced by previous treatment with gold? BMJ 1978; 2: 91

    Article  PubMed  CAS  Google Scholar 

  78. Hill H. Penicillamine and previous treatment with gold. BMJ 1978; 2: 961

    Article  PubMed  CAS  Google Scholar 

  79. Dodd MJ. Adverse reactions to D-penicillamine after gold toxicity. BMJ 1980; 280: 1498–500

    Article  PubMed  CAS  Google Scholar 

  80. Smith PJ. Influence of previous gold toxicity on subsequent development of penicillamine toxicity. BMJ 1982; 285: 595–6

    Article  PubMed  CAS  Google Scholar 

  81. McKenna F, Hopkins R, Hinchcliffe KP, et al. Gold and penicillamine, alone and in combination in active rheumatoid arthritis: a randomized placebo controlled study. Br J Rheumatol 1989; 28: 128–33

    Article  Google Scholar 

  82. Bitter T. Combined disease modifying chemotherapy for intractable rheumatoid arthritis. Clin Rheum Dis 1984; 10: 413–28

    Google Scholar 

  83. Kimberly RP. Glucocorticoid therapy for rheumatic disease. Curr Opin Rheumatol 1992; 4: 325–31

    Article  PubMed  CAS  Google Scholar 

  84. Grauchow LB, Calvin M. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1979; 4: 380–94

    Article  Google Scholar 

  85. Cupps TR, Fanci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128: 2453

    PubMed  CAS  Google Scholar 

  86. Chan GLC. Azathioprine metabolism. J Clin Pharmacol 1990; 30: 358–63

    PubMed  CAS  Google Scholar 

  87. Williams JH, Reading JC, Wand JR, et al. Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 1980; 23: 521–7

    Article  PubMed  CAS  Google Scholar 

  88. Curry HL, Harris J, Mason RM. Comparison of azathioprine, cyclosphosphamide and gold in treatment of rheumatoid arthritis. BMJ 1974; 3: 763–6

    Article  Google Scholar 

  89. Clements PJ, Davis J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum 1986; 15: 231–54

    Article  PubMed  CAS  Google Scholar 

  90. Paulus HE, Williams HJ, Ward JR, et al. Azathioprine versus D-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold. Arthritis Rheum 1984; 27: 721–7

    Article  PubMed  CAS  Google Scholar 

  91. Dwosh IL, Stein HP, Urowitz MB, et al. Azathioprine in early rheumatoid arthritis: comparison with gold and chloroquine. Arthritis Rheum 1977; 20: 685–92

    Article  PubMed  CAS  Google Scholar 

  92. Cade R, Stein G, Pickering M, et al. Low dose long-term treatment of rheumatoid arthritis with azathioprine. South Med J 1976; 69: 388–92

    Article  PubMed  CAS  Google Scholar 

  93. Urowitz MB, Hunter T, Bockman AA, et al. Azathioprine in rheumatoid arthritis: a double blind cross over study. Arthritis Rheum 1973; 16: 411–8

    Article  PubMed  CAS  Google Scholar 

  94. Cox PJ. Cyclophosphamide cystitis and bladder cancer: a hypothesis. Eur J Cancer Clin Oncol 1979; 15: 1071–2

    CAS  Google Scholar 

  95. Baker GL, Klachl LE, Zee BC, et al. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long term case control follow up study. Am J Med 1987; 83: 1–9

    Article  PubMed  CAS  Google Scholar 

  96. Plötz PH. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 1979; 91: 221–3

    PubMed  Google Scholar 

  97. Langeritz P, Maguire L, Urowitz M. Accelerated nodulosis during azathioprine therapy [letter]. Arthritis Rheum 1991; 34: 123–4

    Article  Google Scholar 

  98. Bailey RR. Leucopenia due to a trimethoprim-azathioprine interaction. NZ J Med 1984; 97: 739

    CAS  Google Scholar 

  99. Canvin JMG, Dalal BI, Baragar F. Cyclosporin for the treatment of granulocytopenia in Felty’s syndrome. Am J Hematol 1991; 36: 219–20

    Article  PubMed  CAS  Google Scholar 

  100. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45(6): 953–1040

    Article  PubMed  CAS  Google Scholar 

  101. Van Rijthoven AWAM, Dijikmans BAC, Goei HS, et al. A comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized double blind multicentre study. J Rheumatol 1991; 18: 815–20

    PubMed  Google Scholar 

  102. Ahern MJ, Harrison W, Hollingsworth P, et al. A randomized double blind trial of cyclosporine and azathioprine in refractory rheumatoid arthritis. Aust NZ J Med 1991; 21: 844–9

    Article  CAS  Google Scholar 

  103. Brooks P. Current issues of methotrexate and cyclosporine. Curr Opin Rheumatol 1992; 4: 309–13

    Article  PubMed  CAS  Google Scholar 

  104. Bennett WM, Pulliam JP. Cyclosporine nephrotoxicity. Intern Med 1983; 99: 851–4

    CAS  Google Scholar 

  105. Scott JP, Higenbottom TW. Adverse actions and interactions of cyclosporin. Med Toxicol 1988; 3: 107–27

    Article  CAS  Google Scholar 

  106. Myers BD. Cyclosporine associated chronic nephropathy. N Engl J Med 1984; 311: 699–705

    Article  PubMed  CAS  Google Scholar 

  107. Leunissen KML. Cyclosporin metabolites and nephrotoxicity. Lancet 1986; ii: 1398

    Article  Google Scholar 

  108. Lucey MR. Cyclosporin toxicity at therapeutic blood levels and cytochrome P450. Lancet 1990; 33: 13–5

    Google Scholar 

  109. Praga M. Cyclosporine induced acute renal failure and the nephrotic syndrome. Ann Intern Med 1987; 107: 3–7

    Google Scholar 

  110. Reznik VM. Changes in facial appearance during cyclosporine treatment. Lancet 1987; ii: 1405–7

    Article  Google Scholar 

  111. Atkinson K, Biggs J, Darvenisa P, et al. Cyclosporine-associated CNS toxicity after allogeneic bone marrow transplant. N Engl J Med 1984; 310: 527

    Article  PubMed  CAS  Google Scholar 

  112. Durrant S, Chipping PM, Palmer S, et al. Cyclosporin A, methylprednisolone and convulsions. Lancet 1982; ii: 829–30

    Article  Google Scholar 

  113. Kunzendorf U, Brockmoller J, Jochimsen F, et al. Cyclosporine metabolites and central nervous system toxicity. Lancet 1988; i: 1223

    Article  Google Scholar 

  114. Porter GA. Cyclosporine-associated hypertension. Arch Intern Med 1990; 150: 280–3

    Article  PubMed  CAS  Google Scholar 

  115. June CH. Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients. Transplantation 1986; 41: 47–51

    Article  PubMed  CAS  Google Scholar 

  116. Deray G. Increased endothelin level after cyclosporine therapy. Ann Intern Med 1991; 114: 809

    PubMed  CAS  Google Scholar 

  117. Weinman EJ. Cyclosporine associated hypertension. Am J Med 1989; 86: 256–7

    Article  PubMed  CAS  Google Scholar 

  118. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin: part I. Clin Pharmacokinet 1990; 19: 319–32

    Article  PubMed  CAS  Google Scholar 

  119. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin: part II. Clin Pharmacokinet 1990; 19: 400–15

    Article  PubMed  CAS  Google Scholar 

  120. Tortorice KL. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant patients. Ther Drug Monit 1990; 12: 321–8

    Article  PubMed  CAS  Google Scholar 

  121. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23 Suppl. 1: 82–91

    Article  PubMed  CAS  Google Scholar 

  122. Felson D, Anderson J, Meenan R. Use of short term efficacy/toxicity trade offs to select second line drugs in rheumatoid arthritis: a meta analysis of published clinical trials. Arthritis Rheum 1992; 35: 1117–25

    Article  PubMed  CAS  Google Scholar 

  123. Smith MD. Disease modifying anti-rheumatic drugs: gold, penicillamine, anti-malarials and sulfasalazine. Curr Opin Rheumatol 1990; 2: 489–96

    Article  PubMed  CAS  Google Scholar 

  124. McKenzie HH. Dose requirements in long term therapy of rheumatoid arthritis with anti-malarials. Am J Med 1983; 75 Suppl. 1A: 40–5

    Article  Google Scholar 

  125. Wolfe CS, Hughes GRV. The optimum management of arthropathies. Drugs 1988; 36: 370–81

    Article  PubMed  CAS  Google Scholar 

  126. Ette EI. Pharmacokinetics of chloroquine and some of its metabolites in healthy volunteers: a single dose study. J Clin Pharmacol 1989; 29: 457–62

    PubMed  CAS  Google Scholar 

  127. Parelka Jr K, Parelka Sen K, Pelišková Z, et al. Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens. Ann Rheum Dis 1989; 48: 524–6

    Google Scholar 

  128. Scott DL. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective randomized placebo controlled study. Br J Rheum 1989; 28: 128–33

    Article  CAS  Google Scholar 

  129. Nuver-Zwart IH, van Riel PCM, van de Putte LBA, et al. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect on sulphasalazine. Ann Rheum Dis 1989; 48: 389–95

    Article  PubMed  CAS  Google Scholar 

  130. Finbloom DS, Silver K, Newsome DA, et al. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985; 12: 692–5

    PubMed  CAS  Google Scholar 

  131. Bernstein HN. Ophthalmological considerations and testing in patients receiving long term anti-malarial therapy. Am J Med 1983; 75 Suppl. 1A: 25–34

    Article  PubMed  CAS  Google Scholar 

  132. Easterbrook M. Ocular effects and safety of anti-malarial agents. Am J Med 1988; 85 Suppl. 4A: 23–9

    Article  PubMed  CAS  Google Scholar 

  133. Elman A. Chloroquine retinopathy in patients with rheumatoid arthritis. Scand J Rheumatol 1976; 5: 161–6

    Article  PubMed  CAS  Google Scholar 

  134. Mazzuca SA, Yung R, Brandt KD, et al. Current practices for monitoring ocular toxicity related to hydroxychloroquine therapy. J Rheumatol 1994; 21: 59–64

    PubMed  CAS  Google Scholar 

  135. Fries JF, Williams CA, Ramey D, et al. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36: 297–306

    Article  PubMed  CAS  Google Scholar 

  136. Kushner I. Does aggressive therapy of rheumatoid arthritis affect outcome? J Rheumatol 1989; 16: 1–4

    PubMed  CAS  Google Scholar 

  137. Amor B, Henson D, Cherat A, et al. Polyarthrite rheumatoide evaluant depuis plus de 10 ans (1966-1978). Ann Med Interne (Paris) 1981; 132: 168–73

    CAS  Google Scholar 

  138. Pullar T, Hunter JA, Capell HA. Does second line therapy affect the radiological progression of rheumatoid arthritis? Ann Rheum Dis 1984; 43: 18–23

    Article  PubMed  CAS  Google Scholar 

  139. Scott DL, Symmons DPM, Coulton BL, et al. Long term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987; i: 1108–11

    Article  Google Scholar 

  140. Wolfe F, Hawley DT, Cathey MA. Termination of slow-acting anti-rheumatic therapy in rheumatoid arthritis: a 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994–1007

    PubMed  CAS  Google Scholar 

  141. Arnett FC, Edgworthy SM, Black DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–23

    Article  PubMed  CAS  Google Scholar 

  142. Kaplan-Meier Survival Analysis. SPSS for Windows: Advanced Statistics, Release 6.0: 259–74

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Flinders University of South Australia, Bedford Park, South Australia, 5042, Australia

    Michael J. Ahern

  2. Department of Medicine, Flinders Medical Centre, Bedford Park, South Australia, Australia

    Geetha Chandran

Authors
  1. Michael J. Ahern
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geetha Chandran
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahern, M.J., Chandran, G. Category III Symptom-Modifying Antirheumatic Drugs. Clin. Immunother. 3, 196–217 (1995). https://doi.org/10.1007/BF03259056

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259056

Keywords

Search

Navigation